
# Overactive Bladder

報告者:陳苾琦 藥師 指導藥師:王昭方 藥師 報告日期:2022.11.17



#### **Table of contents**





**UROLOGY - REVIEW** 

# Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis


Zhongyu Jian<sup>1,2</sup> · Chi Yuan<sup>1</sup> · Hong Li<sup>1</sup> · Wei Zhang<sup>2</sup> · Kunjie Wang<sup>1</sup>




# Background



#### **Overactive Bladder**




**Presence of urinary urgency**, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence (UUI), in the **absence of urinary tract infection or other obvious pathology** 



1. International Continence Society: Overactive Bladder

#### Epidemiology





1. Irwin, D.E., Kopp, Z.S., Agatep, B., Milsom, I. and Abrams, P. (2011), Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU International, 108: 1132-1138.

2. Yu HJ, Liu CY, Lee KL, Lee WC, Chen TH: Overactive bladder syndrome among community-dwelling adults in Taiwan: prevalence, correlates, perception, and treatment seeking. UrolInt2006;77:327-33.

## Pathophysiology

#### Normal pathway






### Diagnosis

**Clinical Principle** 

Document symptoms and signs that characterize OAB and **exclude other disorders** 



1.Report from Overactive Bladder Committee

2. Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: AUA/SUFU Guideline (2019)

## **Overactive Bladder Symptom Score (OABSS)**

Question	Frequency	Score
1. How many times do you typically urinate from waking in the morning until sleeping at night	≤ 7 8-14 ≥ 15	0 1 2
2. How many times do you typically wake up to urinate from sleeping at night until walking in the morning?	0 1 2 ≥ 3	0 1 2 3
3. How often do you have a sudden desire to urinate, which is difficult to defer?	Not at all Less than once a week Once a week or more About once a day 2-4 times a day 5 times a day or more	0 1 2 3 4 5
4. How often do you leak urine because you cannot defer the sudden desire to urinate?	Not at all Less than once a week Once a week or more About once a day 2-4 times a day 5 times a day or more	0 1 2 3 4 5

#### Differentiation

**Nocturia** Normal or large volume voids vs Small volume voids

Polydipsia

Use of frequency-volume charts

Interstitial cystitis/bladder pain syndrome

Pelvic pain

**Others condition** Atrophic vaginitis and other infections

1.Report from Overactive Bladder Committee

2. Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: AUA/SUFU Guideline (2019)

DAY 1							
Time	Dri	nks	Urin	e	Accidental Leaks		
	What kind?	How much?	How urgent?	How much?	Y/N		
Example	Coffee	2 Cups	1-3 (3=most urgent)	25 mLs	YES		
6-7 am							
7-8 am							
8-9 am							
9-10 am							
10-11 am							
11-12 midday							
12-1 pm							
1-2 pm							
2-3 pm							
3-4 pm							

#### Treatment



Aim: Relieves symptoms and improve quality of life

#### **Behavioral Treatment**




#### Bladder training

Amount of time between emptying your bladder

Amount of fluids your bladder can hold.

Leakage and the sense of urgency

#### **Treatments' Mode of Action**



#### **Anti-muscarinics**

Oxybutynin (Ditropan)	Oxybutynin transdermal	Oxybutynin gel Propiverine (Urotrol)		Imidafenacin (Uritos)			
Non-selective	Non-selective	Non-selective	Non-selective +CCB	M1, M3 selective			
2.5mg/tab	3.9mg/patch	10% /pack	15mg/tab	0.1mg/tab			
2# BID-TID	1 patch BIW	1 packet QD	1# BID-QID	1# BID			
CYP3A4	Trasndermal	Trasndermal	CYP3A4/Intestinal	CYP3A4			
No dosage adjustment	-	_		CrCl<30: X Moderate /Severe hepatic: X			
Dry mouth, Constipation, Dry eyes, Impaired cognitive function, Urinary retention							
6	X	X	4.63	Х			

#### **Anti-muscarinics**

Solifenacin (Vesicare)	Tolterodine (Terodine)	Trospium (Uracare)						
M3 selective	Non-selective	Non-selective						
5mg/tab	2mg/tab	10mg/tab						
1-2# QD	1# BID	1-2# BID AC						
CYP3A4	CYP3A4	Liver via ester hydrolysis						
CrCl<30: 5mg QD Moderate hepatic: 5mg QD	CrCl<30: 1mg BID Severe hepatic: 1mg BID	CrCl<30: 20mg QD						
Dry mouth, Constipation, Dry eyes, Impaired cognitive function, Urinary retention								
10.7	7.6	4.29						

## **Side Effects Management**

- Manage constipation and dry mouth before abandoning effective anti-muscarinic therapy
  - Adequate dietary fiber and fluid
  - Psyllium-based fiber supplements

- Regular exercise
- Normal bowel habits

- Advice on oral lubricants
- Sucking on sugar-free hard candies

- Taking small sips of water
- Chewing sugar-free gum

#### Vibegron (Gemtasa)



FDA first approval date

**Mechanism of Action** 

**Indications and Usage** 

Overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency


Dosage

75mg QD

2020.12.27 (US)

Beta-3 adrenergic agonist

Taiwan FDA approval







# **Methods**



## **Eligibility Criteria**



#### Outcomes



## Data Analysis

Effect measures	Mean difference (Continuous) / Odds ratio (Dichotomo					
Model	Fixed model (Low heterogeneity studies)					
	Random model (Moderate heterogeneity studies)					
Subgroup analysis	Vibegron 75 mg study enrolled					
Publication bias	Begg funnel plot and Egger test					



## **Results**




#### **Results**

Table 1 Summary of studies included in the systematic review

Study trial number	Intervention (number of patients, <i>n</i> )	Trial design (location)	Patient population	Treatment duration (weeks)
Staskin D 2020 NCT03492281	V 75 mg (547) TER 4 mg (431) Placebo (540)	Phase III, RCT, double-blind, multicenter (US and Canada)	OAB,≥18 years	12
Mitcheson HD 2019 NCT01314872	Part 1: V 3 mg (144), V 15 mg (134), V 50 mg (150), V 100 mg (149), TER 4 mg (135), V 50 mg + TER 4 mg/V 50 mg <sup>a</sup> (134), Placebo (141); Part 2: V 100 mg (112), TER 4 mg (122), V 100 mg + TER 4 mg (110), Placebo (64);	Phase IIb, RCT, double-blind, multicenter (18 countries)	Part 1: OAB, 40–75 years Part 2: OAB, 18–75 years	Part 1: 8 Part 2: 4
Yoshida M 2018 JapicCTI-152800	V 50 mg (118) <sup>b</sup> V 50 mg/V 100 mg <sup>b</sup> (51)	Phase III, open-label, non-con- trolled, multicenter (Japan)	$OAB, \geq 20$ years	52
Yoshida M 2018 Japi- cCTI-152936	V 50 mg (372) V 100 mg (372) Placebo (371) Imidafenacin 0.1 mg twice daily (117)	Phase III, RCT, double-blind, multicenter (Japan)	OAB,≥20 years	12
Yoshida M 2019 Japi- cCTI-152936	V 50 mg (227) V 100 mg (218) Placebo (224)	Post-hoc analysis on nocturia of the trial JapicCTI-152936	OAB,≥20 years	12
Yoshida M 2020 Japi- cCTI-152936	V 50 mg (329) V 100 mg (327) Placebo (333)	Post-hoc analysis on severe urgency urinary incontinence of the trial JapicCTI-152936	$OAB, \geq 20$ years	12


#### **Micturition**

50mg vs Placebo




#### Micturition

50mg vs Antimuscarinics




#### **Micturition**

100mg vs Placebo




#### Micturition

100mg vs Antimuscarinics



#### **Micturition**

100mg vs 50mg



Efficacy The pooled estimates		es Heterogene		rogeneity	Efficacy	The pooled estimate	S	Heteroger		rogeneity	
	Included patients, n	WMD (95%CI)	P value	$I^{2},\%$	P value		Included patients, n	WMD (95%CI)	P value	$I^{2},\%$	P value
Urgency urinary incontinence						Incontinence					
V 50 mg vs Placebo	833/823	- 0.33 (- 0.49, - 0.17)	< 0.001	2.1	0.360	V 50 mg vs Placebo	450/451	- 0.31 (- 0.49, - 0.12)	0.001	0	0.881
V 100 mg vs Placebo	918/876	- 0.43 (- 0.58, - 0.27)	< 0.001	0	0.530	V 100 mg vs Placebo	535/504	- 0.43 (- 0.61, - 0.25)	< 0.001	0	0.750
V 50 mg vs Antimuscarinics	833/488	0.04 (- 0.17, 0.25)	0.721	28.8	0.246	V 50 mg vs Antimuscarinics	450/204	- 0.10 (- 0.52, 0.32)	0.636	57.1	0.127
V 100 mg vs Antimuscarinics	918/590	- 0.11 (- 0.31, 0.09)	0.278	11.7	0.334	V 100 mg vs Antimuscarinics	535/304	- 0.17 (- 0.40, 0.05)	0.137	31.1	0.234
V 100 mg vs 50 mg	494/534	- 0.26 (- 0.57, 0.06)	0.116	50.3	0.134	V 100 mg vs 50 mg	372/422	- 0.39 (- 1.01, 0.24)	0.224	73.9	0.05
Urgency						Voided volume					
V 50 mg vs Placebo	1010/985	- 0.53 (- 0.77, - 0.29)	< 0.001	0	0.914	V 50 mg vs Placebo	860/847	21.8 (19.9, 23.6)	< 0.001	52.4	0.147
V 100 mg vs Placebo	1119/1049	- 0.69 (- 0.92, - 0.45)	< 0.001	24.4	0.265	V 100 mg vs Placebo	858/847	21.4 (19.6, 23.2)	< 0.001	0	0.780
V 50 mg vs Antimuscarinics	1010/629	- 0.06 (- 0.36, 0.24)	0.691	0	0.696	V 50 mg vs Antimuscarinics	860/492	8.24 (6.38, 10.11)	< 0.001	17.4	0.271
V 100 mg vs Antimuscarinics	1119/751	-0.34 (-0.62, -0.06)	0.018	46.9	0.130	V 100 mg vs Antimuscarinics	858/492	8.06 (6.19, 9.93)	< 0.001	0	0.788
V 100 mg vs 50 mg	567/632	- 0.28 (- 0.77, 0.20)	0.257	59.9	0.083	V 100 mg vs 50 mg	419/485	- 4.45 (- 9.82, 0.92)	0.104	0	0.386

## **Results - Safety**

	Safety	The pooled estimates	S		Heter	ogeneity	Safety	The pooled estimates			Heterogeneity	
		Included patients, n	OR (95%CI)	P value	<i>I</i> <sup>2</sup> ,%	P value	2 miles	Included patients, n	OR (95%CI)	P value	$\overline{I^2,\%}$	P value
	Dry mouth						Diarrhea					
V 50 m	g vs Placebo	1063/1114	1.86 (0.92, 3.75)	0.085	0	0.915		1063/1114	1.21 (0.59, 2.44)	0.605	31.4	0.233
04540-0025421	ng vs Placebo	1175/1114	1.04 (1.47, 2.30)	0.918	4.9	0.349		1175/1114	1.18 (0.60, 2.33)	0.640	20.3	0.285
	g vs Antimuscarinics	1063/804	0.30 (0.18, 0.50)	< 0.001	34.6	0.217		1063/804	1.07 (0.59, 1.95)	0.823	5.3	0.348
0.0000000000000000000000000000000000000	ng vs Antimuscarinics	1175/804	0.18 (0.09, 0.33)	< 0.001	10.3	0.328		1175/804	0.69 (0.37, 1.30)	0.249	28.8	0.246
	ng vs 50 mg	681/634	0.66 (0.18, 2.40)	0.531	Version en al	0.089	Cystitis	681/634	1.30 (0.46, 3.64)	0.620	3.1	0.356
	Nasopharyngitis							1063/1114	1.99 (0.92, 4.29)	0.079	0	0.671
		1063/1114	1.19 (0.80, 1.77)	0.397	0	0.475		1175/1114	1.36 (0.64, 2.92)	0.426		0.427
		1175/1114	1.15 (0.78, 1.69)	0.492	51.9	0.125		1063/804	1.36 (0.63, 2.97)	0.436		0.683
		1063/804	1.86 (1.07, 3.23)	0.027	41.7	0.180		1175/804	0.86 (0.40, 1.83)	0.689		0.488
		1175/804	1.83 (1.06, 3.14)	0.029	28.8	0.246		681/634	0.59 (0.31, 1.12)	0.108	0	0.441
		681/634	0.95 (0.64, 1.42)	0.809	0	0.615						
	Constipation											
		1063/1114	1.81 (0.90, 3.66)	0.096	0	0.983						
		1175/1114	0.86 (0.39, 1.88)	0.703	48.5	0.144						
		1063/804	0.88 (0.16, 4.72)	0.879	81.2	0.005						
		1175/804	0.26 (0.14, 0.52)	< 0.001	0	0.868						
		681/634	0.48 (0.07, 3.54)	0.472	120	0.030						



# Discussion

- Vibegron 50mg or 75mg
- Vibegron and Mirabegron comparison
- National Health Insurance Specification
- Others



#### **Other Current Studies**

	EMPOWUR 2020	EMPOWUR Extension 2021	Wever 2021
Study Type	Phase 3	Phase 3, extension	Phase I, ambulatory blood pressure monitoring
Study Duration	12 weeks	52 weeks	28 day
Experimental Group	Vibegron 75mg (N=545)	Vibegron 75mg (N=273)	Vibegron 75mg (N=106)
Control Group	Placebo (N=540) Tolterodine 4mg ER (N=430)	Tolterodine 4mg ER (N=232)	Placebo (N=108)
Outcomes Assessed	Number of micturitions UUI episode Urgency episodes Volume voided Safety	Micturitions, urgency episodes, UUI episodes,† total urinary incontinence episodes† Safety	Mean daytime and 24- hour ambulatory systolic blood pressure, diastolic blood pressure, and heart rate

#### **Other Current Studies**

#### **EMPOWUR**

	Plac	ebo	Vibe	egron	Tolte	rodine
No. pts	520		526		417	
Age:						
Median (IQR)	61.0	(16.0)	63.0	(18.0)	61.0	(17.0)
No. 65 or older (%)	220	(42.3)	242	(46.0)	166	(39.8)
No. 75 or older (%)	57	(11.0)	75	(14.3)	47	(11.3)
No. sex (%):						
Female	445	(85.6)	449	(85.4)	352	(84.4)
Male	75	(14.4)	77	(14.6)	65	(15.6)
No. race (%):						
White	406	(78.1)	422	(80.2)	317	(76.0)
Black/African American	79	(15.2)	74	(14.1)	69	(16.5)
Asian	29	(5.6)	27	(5.1)	26	(6.2)
American Indian or Alaska Native	3	(0.6)	1	(0.2)	0	
Other	3	(0.6)	2	(0.4)	5	(1.2)
No. region (%):						
U.S.	463	(89.0)	472	(89.7)	376	(90.2)
NonU.S.	57	(11.0)	54	(10.3)	41	(9.8)

Vibegron 75mg effect in the Taiwanese population may differ.

#### **Beta-3 Adrenergic Agonists Comparison**

Vibegron (Gemtasa)	Mirabegron (Betmiga)
75mg QD	Initial 25mg QD, titrate to 50 mg QD
99.2%	80.4%
Not measurable/Low	Measurable/Some
Headache, Diarrhea, Nasopharyngitis	Hypertension, Headache, UTI, Tachycardia
Child-Pugh class C or eGFR <15 mL/minute/1.73 m2: Not recommended	<ul> <li>Child-Pugh class B or eGFR 15 to &lt;30 mL/minute/1.73 m2: Do not exceed 25 mg once daily</li> <li>eGFR &lt;15 mL/minute/1.73 m2: Not recommended</li> </ul>
Minor metabolism hepatically via CYP3A4	Multiple pathways, Moderate CYP2D6 inhibitor
-	NTD 36

## **Hypertension Events**


Adverse Events by Treatment Group in the EMPOWUR Trial (Safety Analysis Set)

**EMPOWUR** 

	Placebo	Vibegron	Tolterodine
No. pts	540	545	430
No. summary (%)			
Any AE	180 (33.3)	211 (38.7)	166 (38.6)
Any AE of clinical interest	40 (7.4)	36 (6.6)	38 (8.8)
Any serious AE	6 (1.1)	8 (1.5)	10 (2.3)
Any AE leading to treatment discontinuation	6 (1.1)	9 (1.7)	14 (3.3)
No. by AE preferred term (%)*			
Urinary tract infection	33 (6.1)	27 (5.0)	25 (5.8)
Headache	13 (2.4)	22 (4.0)	11 (2.6)
Nasopharyngitis	9 (1.7)	15 (2.8)	11 (2.6)
Diarrhea	6 (1.1)	12 (2.2)	9 (2.1)
Nausea	6 (1.1)	12 (2.2)	5 (1.2)
Upper respiratory tract infection	4 (0.7)	11 (2.0)	2 (0.5)
Constipation	7 (1.3)	9 (1.7)	6 (1.4)
Dry mouth	5 (0.9)	9 (1.7)	28 (6.5)
Hypertension	9 (1.7)	9 (1.7)	11 (2.6)

Ambulatory BP parameter	<b>Placebo (N = 101)</b>	Vibegron (N = 96)
SBP, mmHg		
Mean (SD) baseline	123.0 (10.0)	122.1 (11.0)
Least squares mean change at day 28 (90% CI)	0.0 (-1.2 to 1.3)	0.6 (-0.7 to 1.9)
Least squares mean difference vs. placebo (90% Cl)	0.6 (-1.0 to 2.1)	
DBP, mmHg		
Mean (SD) baseline	72.6 (7.9)	72.8 (7.6)
Least squares mean change at day 28 (90% CI)	0.7 (-0.2 to 1.6)	0.5 (-0.4 to 1.4)
Least squares mean difference vs. placebo (90% Cl)	-0.2 (-1.3 to 0.9)	

#### Studies shown that Mirabegron can increase blood pressure up to 3.5/1.5 mmHg



**Wever 2021** 

#### **National Health Insurance Specification**

Tolterodine-L-tartrate/ Solifenacin succinate / Mirabegron

#### 限符合下列診斷標準條件之一者


頻尿 (>八次/24小時)、急尿 (突然、很強烈想解尿)、急迫性尿失禁 (24小時內有一次漏尿)

#### 不宜使用本類藥品者

小兒夜尿、單純性應力性尿失禁、膀胱逼尿肌無反射 (detrusor areflexia) 或膀胱不收縮所引起之排尿困難或尿失禁之症狀。

Vesicare / Mirabegron 限用一顆

#### Discussion



#### Discussion

#### Limitations

- ×
- Small number of studies
- X
- One non-RCT included
- ×
- Sensitivity analysis should be treated cautiously
- ×
- Clinical factors affecting efficacy outcome





# Conclusion



### Conclusion

- Vibegron is effective and safe for treating patients with OAB
- Higher volume voided per micturition
- Lower side effects (dry mouth and constipation)
- Lesser drug-drug interactions



Higher risk of nasopharyngitis



- Optimal dose for Taiwanese population
- Head-to-head comparison needed



# Appraisal



## 此回顧是否問了一個明確的問題?



С

Yes

No

Can't tell

1. Did the review address a clearly focused question?

both in vitro and in vivo [6, 7]. Since ben, multiple studies have been performed to compare vibegron with placebo or antimuscarinics for patients with OAB [8–11]. Our systematic review and meta-analysis aimed to assess the efficacy and tolerability of vibegron in patients with OAB. To our knowledge, this is the first systematic review epoloring the role of vibegron in the treatment of OAB.

Primary efficacy: Micturition episodes/24 h Safety outcomes

### 作者是否搜尋適當的文章類型?



#### 2. Did the authors look for the right type of papers?




study design: comparative studies. Case reports, reviews, meta-analysis, meeting abstracts, comments, and letters were excluded.



## 是否所有重要、相關的文獻皆被納入?




3. Do you think all the important, relevant studies were included?



## 作者是否對納入的文獻進行品質評估?



4. Did the review's authors do enough to assess quality of the included studies?



#### 結果的合併是否合理?



5. If the results of the review have been combined, was it reasonable to do so?

Heterogeneity

Almost low to moderate heterogeneity

Micturition					
V 50 mg vs Placebo	1010/985	- 0.82 (- 1.04, - 0.60)	< 0.001	0	0.656
V 100 mg vs Placebo	1119/1049	- 0.83 (- 1.04, - 0.62)	< 0.001	0	0.696
V 50 mg vs Antimuscarinics	1010/629	- 0.09 (- 0.36, 0.18)	0.528	0	0.880
V 100 mg vs Antimuscarinics	1119/803	- 0.33 (- 0.71, 0.05)	0.084	57.8	0.069
V 100 mg vs 50 mg	567/633	- 0.06 (- 0.28, 0.16)	0.576	6.7	0.342

Yes	$\checkmark$
Can't tell	
No	

### 此文章的整體結果為何?



#### 6. What are the overall results of the review?

7. How precise are the results?

Efficacy	The pooled estimates				Heterogeneity	
	Included patients, n	WMD (95%CI)	P value	$\overline{I^{2},\%}$	P value	
Micturition						
V 50 mg vs Placebo	1010/985	- 0.82 (- 1.04, - 0.60)	< 0.001	0	0.656	
V 100 mg vs Placebo	1119/1049	- 0.83 (- 1.04, - 0.62)	< 0.001	0	0.696	
V 50 mg vs Antimuscarinics	1010/629	- 0.09 (- 0.36, 0.18)	0.528	0	0.880	
V 100 mg vs Antimuscarinics	1119/803	- 0.33 (- 0.71, 0.05)	0.084	57.8	0.069	
V 100 mg vs 50 mg	567/633	- 0.06 (- 0.28, 0.16)	0.576	6.7	0.342	
Urgency urinary incontinence						
V 50 mg vs Placebo	833/823	- 0.33 (- 0.49, - 0.17)	< 0.001	2.1	0.360	
V 100 mg vs Placebo	918/876	- 0.43 (- 0.58, - 0.27)	< 0.001	0	0.530	
V 50 mg vs Antimuscarinics	833/488	0.04 (- 0.17, 0.25)	0.721	28.8	0.246	
V 100 mg vs Antimuscarinics	918/590	- 0.11 (- 0.31, 0.09)	0.278	11.7	0.334	
V 100 mg vs 50 mg	494/534	- 0.26 (- 0.57, 0.06)	0.116	50.3	0.134	

Efficacy	The pooled estimates	Heterogeneity			
	Included patients, n	WMD (95%CI)	P value	$I^{2},\%$	P value
Urgency					
V 50 mg vs Placebo	1010/985	- 0.53 (- 0.77, - 0.29)	< 0.001	0	0.914
V 100 mg vs Placebo	1119/1049	- 0.69 (- 0.92, - 0.45)	< 0.001	24.4	0.265
V 50 mg vs Antimuscarinics	1010/629	- 0.06 (- 0.36, 0.24)	0.691	0	0.696
V 100 mg vs Antimuscarinics	1119/751	- 0.34 (- 0.62, - 0.06)	0.018	46.9	0.130
V 100 mg vs 50 mg	567/632	- 0.28 (- 0.77, 0.20)	0.257	59.9	0.083

#### 此文章的整體結果為何?



### 6. What are the overall results of the review?

7. How precise are the results?

Efficacy	The pooled estimates	Heterogeneity			
	Included patients, n	WMD (95%CI)	P value	$I^{2},\%$	P value
Incontinence					
V 50 mg vs Placebo	450/451	- 0.31 (- 0.49, - 0.12)	0.001	0	0.881
V 100 mg vs Placebo	535/504	- 0.43 (- 0.61, - 0.25)	< 0.001	0	0.750
V 50 mg vs Antimuscarinics	450/204	- 0.10 (- 0.52, 0.32)	0.636	57.1	0.127
V 100 mg vs Antimuscarinics	535/304	- 0.17 (- 0.40, 0.05)	0.137	31.1	0.234
V 100 mg vs 50 mg	372/422	- 0.39 (- 1.01, 0.24)	0.224	73.9	0.05
Voided volume					
V 50 mg vs Placebo	860/847	21.8 (19.9, 23.6)	< 0.001	52.4	0.147
V 100 mg vs Placebo	858/847	21.4 (19.6, 23.2)	< 0.001	0	0.780
V 50 mg vs Antimuscarinics	860/492	8.24 (6.38, 10.11)	< 0.001	17.4	0.271
V 100 mg vs Antimuscarinics	858/492	8.06 (6.19, 9.93)	< 0.001	0	0.788
V 100 mg vs 50 mg	419/485	- 4.45 (- 9.82, 0.92)	0.104	0	0.386

Efficacy outcomes
<b>No significant difference</b> for 100mg vs 50mg in any outcome
A significant difference in voided volume when compared to antimuscarinics

#### 此文章的整體結果為何?



#### 6. What are the overall results of the review?

#### 7. How precise are the results?

	Safety	The pooled estimates		Heterogeneity Safety Th		The pooled estimates	The pooled estimates			rogeneity		
		Included patients, n	OR (95%CI)	P value	$I^{2},\%$	P value		Included patients, n	OR (95%CI)	P value	<i>I</i> <sup>2</sup> ,%	P value
-	Dry mouth						Diarrhea					
V 50 m	g vs Placebo	1063/1114	1.86 (0.92, 3.75)	0.085	0	0.915		1063/1114	1.21 (0.59, 2.44)	0.605	31.4	0.233
V 100 r	ng vs Placebo	1175/1114	1.04 (1.47, 2.30)	0.918	4.9	0.349		1175/1114	1.18 (0.60, 2.33)	0.640	20.3	0.285
	g vs Antimuscarinics	1063/804	0.30 (0.18, 0.50)	< 0.001	34.6	0.217		1063/804	1.07 (0.59, 1.95)	0.823	5.3	0.348
	ng vs Antimuscarinics	1175/804	0.18 (0.09, 0.33)	< 0.001	10.3	0.328		1175/804	0.69 (0.37, 1.30)	0.249	28.8	0.246
	ng vs 50 mg	681/634	0.66 (0.18, 2.40)	0.531	58.7	0.089	Cystitis	681/634	1.30 (0.46, 3.64)	0.620	3.1	0.356
	Nasopharyngitis							1063/1114	1.99 (0.92, 4.29)	0.079	0	0.671
		1063/1114	1.19 (0.80, 1.77)	0.397	0	0.475		1175/1114	1.36 (0.64, 2.92)	0.426	0	0.427
		1175/1114	1.15 (0.78, 1.69)	0.492	51.9	0.125		1063/804	1.36 (0.63, 2.97)	0.436	0	0.683
		1063/804	1.86 (1.07, 3.23)	0.027	41.7	0.180		1175/804	0.86 (0.40, 1.83)	0.689	0	0.488
		1175/804	1.83 (1.06, 3.14)	0.029	28.8	0.246		681/634	0.59 (0.31, 1.12)	0.108	0	0.441
		681/634	0.95 (0.64, 1.42)	0.809	0	0.615						
	Constipation							Sa	afety outo	come	S	
		1063/1114	1.81 (0.90, 3.66)	0.096	0	0.983						
		1175/1114	0.86 (0.39, 1.88)	0.703	48.5	0.144		Higher ris	sk of nasop	oharyı	ngiti	is
		1063/804	0.88 (0.16, 4.72)	0.879	81.2	0.005						
		1175/804	0.26 (0.14, 0.52)	< 0.001	0	0.868		l ower risk	Lower risk of dry mouth			
		681/634	0.48 (0.07, 3.54)	0.472	71.6	0.030						

## 此研究結果是否可應用到當地的族群?

8. Can the results be applied to the local population?

Domains	This study
Target population	Overactive bladder
Location	USA, Japan
Intervention	Vibegron vs placebo/antimuscarinics
Evaluation	Primary outcome: Micturition Safety outcomes





#### 所有重要的結果都有被考慮?



53

#### 9. Were all important outcomes considered?

	Domains		
Efficacy	<ul> <li>Micturition episodes/24 h</li> <li>Urgency urinary incontinence (UUI) episodes/24 h</li> <li>Urgency episodes/24 h</li> <li>Incontinence episodes/24 h</li> <li>Voided volume/micturition</li> </ul>		
Safety	<ul> <li>Dry mouth</li> <li>Nasopharyngitis</li> <li>Constipation</li> <li>Diarrhea</li> <li>Cystitis</li> </ul>	Yes Can't tell No	

### 此文章的利大於弊・且符合成本效益?



10. Are the benefits worth the harms and costs?

	Vibegron	Antimuscarinics
Efficacy	Higher voided vo	olume in vibegron
Safety	Higher risk of nasopharyngitis	Higher risk of dry mouth, constipation
Cost	TFDA not yet approved	Solifenacin 一次一錠







V		Р
問題明確	結果	應用至本地 🔵 🔵
	Vibegron is <b>effective and safe</b> for treating patients with OAB	
蒐納適當	for freating patients with one	重要結果
廣泛搜尋	精準	利大於弊
品質評估	大部分結果之信賴區間窄,分析 結果之 <mark>篇數稍嫌少</mark>	
結果合併		

#### References

- 1. International Continence Society: Overactive Bladder
- 2. Report from Overactive Bladder Committee
- Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: AUA/SUFU Guideline (2019)
- Uptodate: Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment
- 5. Vibegron FDA Label

# Thanks

57

Do you have any questions?